All patients with ALK-rearranged Sq-LC had previously undergone standard chemotherapy for Sq-LC prior to treatment with crizotinib and switched regimens when ALK rearrangement was detected, when they were diagnosed with progressive disease (PD) during ongoing chemotherapy, or when they showed severe adverse effects after detection of ALK rearrangement. Here, ALK is linked to laryngotracheoesophageal cleft.